Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Novo Nordisk posted solid quarterly results Wednesday before the market open.The drug maker’s sales came in at 71.3 billion ...

Novo Nordisk A/S’s sales of blockbuster weight-loss drug Wegovy beat expectations in the third quarter, a potential relief ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Novo Nordisk's net profit in the third quarter rose 21% to 27.3 billion kroner, ahead of the 26.79 billion kroner forecast by analysts in a FactSet poll. Sales rose 21% to 71.31 billion kroner, ...

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

People who have obesity regularly report medical providers are rude or dismissive toward them, research shows, which can lead ...